Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2005-03-24
2010-02-16
Yu, Misook (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S134100, C530S387300
Reexamination Certificate
active
07662384
ABSTRACT:
The present invention provides methods for direct killing of cancer cells using anti-α5β1 antibodies. Generally, the method comprises contacting a cancer cell that expresses α5β1 on its surface with an anti-α5β1 antibody, and thereby inducing the death of the cancer cell. The methods of the invention may be employed at an early stage of cancer development in a patient to prevent tumor establishment. In addition, the methods may be used to treat previously formed tumors especially in cancer that have not proven susceptible to anti-angiogenesis therapy. The methods may be employed as a combination therapy of anti-α5β1 antibodies together with cancer chemotherapeutic agents or other molecular-based cancer therapeutic agents.
REFERENCES:
patent: 4704366 (1987-11-01), Juarez-Salinas et al.
patent: 4801687 (1989-01-01), Ngo
patent: 4935496 (1990-06-01), Kudo
patent: 4946778 (1990-08-01), Ladner
patent: 5502167 (1996-03-01), Waldmann
patent: 5530101 (1996-06-01), Queen et al.
patent: 5536814 (1996-07-01), Ruoslahti
patent: 5558864 (1996-09-01), Bendig
patent: 5639641 (1997-06-01), Pedersen
patent: 5677181 (1997-10-01), Parish
patent: 5693493 (1997-12-01), Robinson
patent: 5698417 (1997-12-01), Robinson
patent: 5705154 (1998-01-01), Dalie
patent: 5750078 (1998-05-01), Shitara
patent: 5770403 (1998-06-01), Abrams
patent: 5874081 (1999-02-01), Parish
patent: 5922676 (1999-07-01), Pasqualini
patent: 6123941 (2000-09-01), Bissell et al.
patent: 6171586 (2001-01-01), Lam et al.
patent: 6852318 (2005-02-01), Varner
patent: 2002/0172675 (2002-11-01), Varner
patent: 2004/0077544 (2004-04-01), Varner
patent: 2004/0259152 (2004-12-01), Murray et al.
patent: 2005/0002930 (2005-01-01), Johnson et al.
patent: 2005/0054834 (2005-03-01), Ramakrishnan et al.
patent: 0 896 002 (1999-02-01), None
patent: WO 95/14714 (1995-06-01), None
patent: WO 95/22618 (1995-08-01), None
patent: WO 97/33887 (1997-09-01), None
patent: WO 99/37329 (1999-07-01), None
patent: WO 99/55913 (1999-11-01), None
patent: WO 99/58139 (1999-11-01), None
patent: WO 01/11086 (2001-02-01), None
patent: WO 01/53262 (2001-07-01), None
patent: WO 01/53297 (2001-07-01), None
patent: WO 01/54723 (2001-08-01), None
patent: WO 02/079492 (2002-10-01), None
patent: WO 2004/056308 (2004-07-01), None
patent: WO 2004/110498 (2004-12-01), None
patent: PCT/US2004/010422 (2005-02-01), None
Duro, et al., International Journal of Pharmaceutics, May 14, 1998, pp. 211-216.
: Mahler et al., European Journal of Pharmaceutics, vol. 59, pp. 407-417, Jan. 19, 2005.
Conforti, et al., “Human endothelial cells express integrin receptors on the luminal aspect of their membrane,”Blood, 80(2):437-446 (1992).
Varner, et. al, “Antagonist of Vascular Cell Integrin Alpha5beta1 Inhibit Angiogenesis”Circulation, American Heart Association, 98(17):abstract (1998).
Wu, H., et. al., “The Expression Of Integrin Alph5beta1 And Transforming Growth Factor-Beta In Pulmonary Fibrosis Of Rat”Chinese Journal of Pathology, 28(6): abstract (1999).
Zhao, Ming Wei et. al., A Distinct Integrin-Mediated Phagocytic Pathway For Extracellular Matrix Remodeling By RPE Cells:Invest. Ophthalmol. Vis. Sci., 40(11):2713-2723 (1999).
Wilson, Sylvia et. al.,. “Fibronectin Fragments Promote Human Retinal Endothelial Cell Adhesion and Proliferation and ERK Activation Through Alph5beta1 Integrin and PI 3-Kinase”Invest. Ophthalmol. Vis. Sci., 44(4):1704-1715 (2003).
Loike, J.D. et. al., “Blockade Of Alpa 5 Beta 1 Integrins Reverses The Inhibitory Effect Of Tenacin On Chemotaxis Of Human Monocytes And Polymorphonuclear Leukocytes Through Three-Dimensional Gels Of Extracellular Matrix Proteins”Journal of Immunology166(12):7534-7542 2001.
Kim, Semi et. al., “Regulation Of Integrin Alpha5beta3-Mediated Endothelial Cell Migration And Angiogenesis By Integrin Alpha5beta1 And Protein Kinase A”Journal of Biological Chemistry, 275(43):33920-33928 (2000).
Tolentino, Michael, J., et. al., “Angiography Of Fluoresceinated Anti-Vascular Endothelial Growth Factor Antibody And Dextrans In Experimental Choroidal Neovascularization”Archives of Ophthalmology, 118(1):78-84 (2000).
Ryan, S.J., “The Development Of An Experimental Model Of Subretinal Neovascularization In The Disciform Macular Degeneration”Transactions of the American Ophthalmological Society77:707-745, (1979).
Grossniklaus, Hans et. al., “Immunohistochemical And Histochemcial Properties Of Surgically Excised Subretinal Neovascular Membranes In Age-Related Macular Degeneration”American Journal of Ophthalmology114(4):464-472 (1992).
PCT/US05/09939: International Search Report, Mar. 24, 2005.
Storgard, Chris M. et al., “Decreased Angiogenesis and Arthritic Disease in rabbits Treated with an αvβ3 Antagonist”,The Journal of clinical Investigation, vol. 103 (1999), pp. 47-54.
Ryan, S.J., “Subretinal Neovascularization: Natural History of an Experimental Model”,Archives of Ophthalmology, vol. 100 (1982), pp. 1804-1809.
Rudikoff et al., P.N.A.S. USA, vol. 79 (1982), pp. 1979-83.
Pytela et al., Cell, vol. 40 (1985), pp. 191-198.
Thorpe et al., “Monoclonal Antibodies in Biological Clinical Applications”, (1985), pp. 475-506.
Argraves et al.,J. Biol. Chem., vol. 261(28) (1986), pp. 12922-12924.
Amit, et. al.,Science, vol. 233 (1986), pp. 747-753.
Hackett, R., et al., (1996) Dermatotoxicology. 5thEdition. (Ed. By F.B. Marzulli and H.I. Maibach) Hemisphere Publishing Corp., Washington, D.C.
Varner et. al., “Inteqrins and Cancer”,Current Opinion in Cell Biology, vol. 8(5) (1996), pp. 724-730.
Varner et al., “Tumor Angiogenesis and the Role of Vascular Cell Integrin Alphavbeta3,”Important Advances in Oncology. (1996), pp. 69-87.
Van Der Loo Johannes C.M. et.al., “VLA-5 is Expressed by Mouse and Human Long-Term Repopulating Hematopoietic Cells and Mediates Adhesion to Extracellular Matrix Protein Fibronectin”,Journal of Clinical Investigation, vol. 102 (5) (1998), pp. 1051-1061.
Wu, et. al.,J. Mol. Biol., vol. 294 (1999), pp. 151-162.
Edelman and Castro, “Quantitative Image Analysis of Laser-Induced Choroidal Neovascularization in Rat.”Exp. Eve Res. vol. 71 (2000). pp. 523-533.
Kim, S. et.al., “Regulation of Angiogenesis in Vivo by Ligation of Integrin Alpha5beta1 with the Central Cell-Binding Domain of Fibronectin”,American Journal of Pathology, vol. 156 (4) (2000), pp. 2000-2004.
Wong, et. al.,Current Eye Research, vol. 22(2) (2001), pp. 140-147.
Sequence search alignment for SEQ ID NOS: 1 and 7 (pp. 1-2).
Zhao, et. al.,J. Cell Biol., vol. 152 (9) (2001), pp. 65-71.
Josic, D. et.al., “Analytical and Preparative Methods for Purification of Antibodies”,Food Technology and Biotechnology, vol. 39 (3) (2001), pp. 215-226.
03796541.5, Supplementary European search report, Aug. 24, 2007.
Vajdos, et. al.,J. Molec. Biol., vol. 320 (2002), pp. 415-428.
“Eos Biotechnology Files Investigational New Drug for Novel Targets with Anti-Angiogenic Properties”, www.pharmabiz.com/article/detnews.asp?articleid=13491§ionid=14&z=y>, (2002).
“Protein Design Labs to Acquire Eos Biotechnology”, www.pharmabiz.com/article/detnews.asp?articleid=14199§ionid=14&z=y>, (2003).
Proulx et al., “Effect of Quiescence on Integrin ÿÿ Expression in Human Retinal Pigment Epithelium”,Molecular Vision. vol. 9 (2003) pp. 473-481.
Ramakrishnan Vanitha et.al., “A Function-Blocking Chimeric Antibody Eos200-4, Against Alpha5beta1 Integrin Inhibits Angiogenesis in a Monkey Model”,Proceedings of the American Association for Cancer Research Annual Meeting, vol. 44 (2003), pp. 605-606.
Ho Sun K. et al., “The Effect of a Chimeric Anti-Integrin Alpha5beta1 Antibody (M200) on the Migration of HUVECs and Human Cancer Cells”,Proceedings of the American Association for Cancer Research Annual Meeting,
Bhaskar Vinay
Ho Sun
Law Debbie
Murray Richard
Ramakrishnan Vanitha
Facet Biotech Corporation
Sughrue & Mion, PLLC
Yu Misook
LandOfFree
Use of anti-α5β1 antibodies to inhibit cancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of anti-α5β1 antibodies to inhibit cancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of anti-α5β1 antibodies to inhibit cancer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4193297